Protective effects of valproic acid, a histone deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model
dc.contributor.author | Cetinkaya, Merih | |
dc.contributor.author | Cekmez, Ferhat | |
dc.contributor.author | Tayman, Cuneyt | |
dc.contributor.author | Canpolat, Fuat Emre | |
dc.contributor.author | Kramer, Boris W. | |
dc.contributor.author | Sarici, Serdar Umit | |
dc.contributor.buuauthor | Cansev, Mehmet | |
dc.contributor.buuauthor | Kafa, Ilker Mustafa | |
dc.contributor.buuauthor | Yaylagul, Esra Orenlili | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Farmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Anatomi Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0003-2918-5064 | tr_TR |
dc.contributor.orcid | 0000-0001-8309-0934 | tr_TR |
dc.contributor.orcid | 0000-0002-5206-1185 | tr_TR |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.contributor.researcherid | AAG-7125-2021 | tr_TR |
dc.contributor.researcherid | ABH-4915-2020 | tr_TR |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 8450193200 | tr_TR |
dc.contributor.scopusid | 55618956600 | tr_TR |
dc.date.accessioned | 2023-10-06T07:44:48Z | |
dc.date.available | 2023-10-06T07:44:48Z | |
dc.date.issued | 2015-05-04 | |
dc.description.abstract | Objective: Histone acetylation and deacetylation may play a role in the pathogenesis of inflammatory lung diseases. We evaluated the preventive effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on neonatal hyperoxic lung injury. Methods: Forty newborn rat pups were randomized in normoxia, normoxia+VPA, hyperoxia and hyperoxia+VPA groups. Pups in the normoxia and normoxia+VPA groups were kept in room air and received daily saline and VPA (30 mg/kg) injections, respectively, while those in hyperoxia and hyperoxia+VPA groups were exposed to 95% O2 and received daily saline and VPA (30 mg/kg) injections for 10 days, respectively. Growth, histopathological, biochemical and molecular biological indicators of lung injury, apoptosis, inflammation, fibrosis and histone acetylation were evaluated. Results: VPA treatment during hyperoxia significantly improved weight gain, histopathologic grade, radial alveolar count and lamellar body membrane protein expression, while it decreased number of TUNEL(+) cells and active Caspase-3 expression. Expressions of TGFβ3 and phospho-SMAD2 proteins and levels of tissue proinflammatory cytokines as well as lipid peroxidation biomarkers were reduced, while anti-oxidative enzyme activities were enhanced by VPA treatment. VPA administration also reduced HDAC activity while increasing acetylated H3 and H4 protein expressions. Conclusions: The present study shows for the first time that VPA treatment ameliorates lung damage in a neonatal rat model of hyperoxic lung injury. The preventive effect of VPA involves HDAC inhibition. | en_US |
dc.identifier.citation | Cetinkaya, M. vd. (2015). "Protective effects of valproic acid, a histone deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model". PLoS ONE, 10(5). | en_US |
dc.identifier.issn | 1932-6203 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 25662067 | tr_TR |
dc.identifier.scopus | 2-s2.0-84929378065 | tr_TR |
dc.identifier.uri | https://doi.org/10.1371/journal.pone.0126028 | |
dc.identifier.uri | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126028 | |
dc.identifier.uri | http://hdl.handle.net/11452/34237 | |
dc.identifier.volume | 10 | tr_TR |
dc.identifier.wos | 000353943000132 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Public Library Science | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | PLoS ONE | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Science & Technology - Other topics | en_US |
dc.subject | Gene-expression | en_US |
dc.subject | BCL-2 | en_US |
dc.subject | Pathogenesis | en_US |
dc.subject | Exposure | en_US |
dc.subject | Pathway | en_US |
dc.subject | LPS | en_US |
dc.subject | BAX | en_US |
dc.subject | Rattus | en_US |
dc.subject.emtree | Caspase 3 | en_US |
dc.subject.emtree | Histone H3 | en_US |
dc.subject.emtree | Histone H4 | en_US |
dc.subject.emtree | Interleukin 1beta | en_US |
dc.subject.emtree | Interleukin 6 | en_US |
dc.subject.emtree | Protein bcl 2 | en_US |
dc.subject.emtree | Smad2 protein | en_US |
dc.subject.emtree | Transforming growth factor beta1 | en_US |
dc.subject.emtree | Transforming growth factor beta3 | en_US |
dc.subject.emtree | Tumor necrosis factor alpha | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Histone deacetylase inhibitor | en_US |
dc.subject.emtree | Protective agent | en_US |
dc.subject.emtree | Protein bcl 2 | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Animal tissue | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cell count | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug response | en_US |
dc.subject.emtree | Enzyme activity | en_US |
dc.subject.emtree | Histone acetylation | en_US |
dc.subject.emtree | Hyperoxia | en_US |
dc.subject.emtree | Lipid peroxidation | en_US |
dc.subject.emtree | Lung injury | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Pneumonia | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Protein function | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Weight gain | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Body weight | en_US |
dc.subject.emtree | Complication | en_US |
dc.subject.emtree | Disease model | en_US |
dc.subject.emtree | Lung injury | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Mortality | en_US |
dc.subject.emtree | Oxidation reduction reaction | en_US |
dc.subject.emtree | Oxidative stress | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Biomarkers | en_US |
dc.subject.mesh | Body weight | en_US |
dc.subject.mesh | Caspase 3 | en_US |
dc.subject.mesh | Disease models, Animal | en_US |
dc.subject.mesh | Histone deacetylase inhibitors | en_US |
dc.subject.mesh | Hyperoxia | en_US |
dc.subject.mesh | Lung injury | en_US |
dc.subject.mesh | Oxidation-reduction | en_US |
dc.subject.mesh | Oxidative stress | en_US |
dc.subject.mesh | Protective agents | en_US |
dc.subject.mesh | Proto-oncogene proteins c-bcl-2 | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Valproic acid | en_US |
dc.subject.scopus | Histone deacetylase inhibitors; Valproic acid; Animals | en_US |
dc.subject.wos | Multidisciplinary sciences | en_US |
dc.title | Protective effects of valproic acid, a histone deacetylase inhibitor, against hyperoxic lung injury in a neonatal rat model | en_US |
dc.type | Article | |
dc.wos.quartile | Q1 | en_US |